{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:46:34Z","timestamp":1789631194845,"version":"build-2803163510"},"reference-count":44,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.3111\/13696998.2014.923891","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T11:54:31Z","timestamp":1400154871000},"page":"587-598","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":59,"title":["Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin"],"prefix":"10.3111","volume":"17","author":[{"given":"T.","family":"Lanitis","sequence":"first","affiliation":[{"name":"Evidera, Modeling and Simulation, Health Economics","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. E.","family":"Cott\u00e9","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Health Economics & Outcomes Research","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. F.","family":"Gaudin","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Health Economics & Outcomes Research","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kachaner","sequence":"additional","affiliation":[{"name":"Pfizer, Health Economics & Outcomes Research","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kongnakorn","sequence":"additional","affiliation":[{"name":"Evidera, Modeling and Simulation, Health Economics","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Durand-Zaleski","sequence":"additional","affiliation":[{"name":"URC Eco (Paris Health Services and Health Economics Research Unit, AP-HP)","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,5,29]]},"reference":[{"key":"e_1_3_2_2_1","first-page":"302","article-title":"Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people","volume":"106","author":"Hanon OAP","year":"2013","unstructured":"Hanon OAP, Belmin J, Collet JP, et al. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Arch Cardiovasc Dis 2013;106:302-23","journal-title":"Arch Cardiovasc Dis"},{"key":"e_1_3_2_3_1","unstructured":"Fery-Lemonnier E. La pr\u00e9vention et la prise en charge des accidents vasculaires c\u00e9r\u00e9braux en France: Synth\u00e8se du rapport \u00e0 Madame la ministre de la sant\u00e9 et des sports. Ministere De La Sante Et Des Sports 2009. Available at: http:\/\/www.sante.gouv.fr\/IMG\/pdf\/AVC_synthese_seule_rapport_final_vf.pdf"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12143"},{"key":"e_1_3_2_5_1","unstructured":"ISMAAP. International Self Monitoring Association of oral Anticoagulated patients. Available at: http:\/\/www.ismaap.org"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eur263"},{"key":"e_1_3_2_7_1","first-page":"199, 201","article-title":"[Antithrombotic management in atrial fibrillation]","volume":"63","author":"Fauchier L","year":"2013","unstructured":"Fauchier L, Taillandier S, Clementy N. [Antithrombotic management in atrial fibrillation]. Rev Prat 2013;63:199, 201-6","journal-title":"Rev Prat"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2261-13-71","article-title":"There are considerable drawbacks to oral anticoagulant for monitoring patients at home which should lead family physicians to discuss alternative or enhanced solutions: a cross-sectional study","volume":"13","author":"Le Reste JY CB","year":"2013","unstructured":"Le Reste JY CB, Le Floch B, Nabbe P, et al. There are considerable drawbacks to oral anticoagulant for monitoring patients at home which should lead family physicians to discuss alternative or enhanced solutions: a cross-sectional study. BMC Cardiovasc Disord 2013;13:71","journal-title":"BMC Cardiovasc Disord"},{"key":"e_1_3_2_9_1","first-page":"e259","article-title":"[Atrial fibrillation and anticoagulation: general practitioner, cardiologist and patient's points of view]","volume":"42","author":"Liard F","year":"2013","unstructured":"Liard F, Le Heuzey JY, Aliot E, et al. [Atrial fibrillation and anticoagulation: general practitioner, cardiologist and patient's points of view]. Presse Med 2013;42:e259-70","journal-title":"Presse Med"},{"key":"e_1_3_2_10_1","first-page":"151","article-title":"[Management of atrial fibrillation in France: the observational FACTUEL study]","volume":"58","author":"Mabo P","year":"2009","unstructured":"Mabo P, Leenhardt A, Jaillon P, et al. [Management of atrial fibrillation in France: the observational FACTUEL study]. Ann Cardiol Angeiol (Paris) 2009;58:151-8","journal-title":"Ann Cardiol Angeiol (Paris)"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs253"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007432"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht134"},{"key":"e_1_3_2_17_1","article-title":"Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey","author":"Elewa HF","year":"2013","unstructured":"Elewa HF, Deremer CE, Keller K, et al. Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. J Thromb Thrombolysis 2013 (epub ahead of print)","journal-title":"J Thromb Thrombolysis"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S56187"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/MJT.0b013e3182373591","article-title":"Study of warfarin patients investigating attitudes toward therapy change (SWITCH Survey)","volume":"19","author":"Attaya S","year":"2012","unstructured":"Attaya S, Bornstein T, Ronquillo N, et al. Study of warfarin patients investigating attitudes toward therapy change (SWITCH Survey). Am J Ther 2012;19:432-5","journal-title":"Am J Ther"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2013044"},{"key":"e_1_3_2_21_1","article-title":"Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation","author":"Dorian P","year":"2014","unstructured":"Dorian P, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J 2014 (epub ahead of print)","journal-title":"Eur Heart J"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.12.011"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"e_1_3_2_24_1","unstructured":"Haute autorit\u00e9 de sant\u00e9 (HAS). A methodological guide. Choices in methods for economic evaluation. Department of Economics and Public Health Assessment 2012. Available at: http:\/\/www.has-sante.fr"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.08.022"},{"key":"e_1_3_2_26_1","unstructured":"Ministry of Health. National Hospital Tariff. Official Journal of the French Republic. 2011. Available at: http:\/\/www.journal-officiel.gouv.fr."},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.acvd.2010.06.001","article-title":"Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study","volume":"103","author":"Cohen A","year":"2010","unstructured":"Cohen A, Dallongeville J, Durand-Zaleski I, et al. Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch Cardiovasc Dis 2010;103:376-87","journal-title":"Arch Cardiovasc Dis"},{"key":"e_1_3_2_28_1","unstructured":"Pricing Comittee (CEPS). Drug price database for France. Available at: http:\/\/www.medicprix.sante.gouv.fr. Last accessed 31st December 2013"},{"key":"e_1_3_2_29_1","unstructured":"National Health Insurance Fund for Salaried Worker (CNAMTS). National tariffs for biological and nursing acts. 2011. Available at: http:\/\/www.ameli.fr"},{"key":"e_1_3_2_30_1","unstructured":"Haute autorit\u00e9 de sant\u00e9 (HAS). Fibrillation auriculaire. Available at: www.has-sante.fr. Accessed Juillet 200."},{"key":"e_1_3_2_31_1","unstructured":"Ministry of Health. Prevention and management of stroke in France. 2009. Available at: http:\/\/www.sante.gouv.fr\/IMG\/pdf\/AVC_rapport_final_vf.pdf"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X11401031"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/archinte.1996.00440150083009","article-title":"The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life","volume":"156","author":"Gage BF CA","year":"1996","unstructured":"Gage BF CA, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. JAMA Intern Med 1996;156:1829-36","journal-title":"JAMA Intern Med"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1629"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.142158"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1161\/CIRCOUTCOMES.112.966572","article-title":"Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation","volume":"5","author":"Baker WL","year":"2012","unstructured":"Baker WL, Phung OJ. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:7119","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.01.009"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.000402"},{"key":"e_1_3_2_39_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/clpt.2013.83","article-title":"Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation","volume":"94","author":"Pink J","year":"2013","unstructured":"Pink J, Pirmohamed M, Hughes DA. Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. Clin Pharmacol Ther 2013;94:269-76","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_2_40_1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jama.2010.1161","article-title":"Minimizing bias in randomized trials: the importance of blinding","volume":"304","author":"Psaty BM","year":"2010","unstructured":"Psaty BM, Prentice RL. Minimizing bias in randomized trials: the importance of blinding. JAMA 2010;304:793-4","journal-title":"JAMA"},{"key":"e_1_3_2_41_1","doi-asserted-by":"crossref","unstructured":"Carrasco J Cott\u00e9 FE Duprat Lomon I et al. Anticoagulation treatment with VKA in France Italy Germany Spain and United Kingdom. Results from the React AF study. Value in Health 2013;16:A516","DOI":"10.1016\/j.jval.2013.08.1224"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.019"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.112.965988"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E464"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3111\/13696998.2014.923891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:19:06Z","timestamp":1770373146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3111\/13696998.2014.923891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,29]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.3111\/13696998.2014.923891"],"URL":"https:\/\/doi.org\/10.3111\/13696998.2014.923891","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-05-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}